Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...

The stock's fall snapped a three-day winning streak.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." Merck KGaA (OTC:MKGAF) is seeking worldwide regulatory approval for its ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...